Hodgkin Lymphoma Video Channel
Explore the latest insights and summaries from experts in Hodgkin Lymphoma.
Therapeutic Agents
No available content for Therapeutic Agents, yet.
Therapeutic Agents
Rush University Medical Center
Challenges and Treatment Strategies in Advanced Stage Hodgkin Lymphoma
FEATURING
Saira Ahmed
- 45 views
- June 14, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Treatment of Advanced Stage, High-Risk Hodgkin's Lymphoma With AVD+BV+Nivo
FEATURING
Maher Salamoon
- 163 views
- July 9, 2024
- 5
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Limited Stage HL - Current SOC, Future Directions, and Incorporating BV and Nivo
FEATURING
Steven Park
- 60 views
- July 18, 2024
- 1
UChicago Medicine
Current Standard of Care in Second Line Treatment for Hodgkin Lymphoma
FEATURING
Sarah Rutherford
- 40 views
- July 29, 2024
UChicago Medicine
Are Checkpoint Inhibitors the SOC in Frontline Hodgkin Lymphoma?
FEATURING
Boyu Hu
- 28 views
- July 29, 2024
- 1
University of Miami Sylvester Comprehensive Cancer Center
Current Treatment of 1L Hodgkin Lymphoma
FEATURING
Craig Moskowitz
- 516 views
- August 2, 2024
- 2
UChicago Medicine
Managing Toxicity in Pts With cHL Receiving Checkpoint Inhibitors or ADCs
FEATURING
Rebecca Follenweider
- 24 views
- July 22, 2024
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
2024 Updates in Management of Hodgkin Lymphoma
FEATURING
Jakub Svoboda
- 120 views
- March 13, 2024
UChicago Medicine
Practice-Changing Abstracts in NHL and HL From ASH 2023
FEATURING
Sonali Smith
- 403 views
- March 19, 2024
- 3
SOHO Highlights: State of the Art and Next Questions
State of the Art and Next Questions: Hodgkin Lymphoma
FEATURING
Alex Herrera
- 64 views
- March 22, 2024
ecancer
ASH 2023 Insights: "BrECADD Combined With PET2-Guided Treatment for 1L Adult Pts With Advanced Stage cHL"
FEATURING
Peter Borchmann
- 44 views
- January 19, 2024
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 Next Questions: HL
FEATURING
Alex Herrera
- 126 views
- October 19, 2023
NYU Langone
Targeted Treatment Strategies in Hematologic Malignancies
FEATURING
Tibor Moskovits
- 37 views
- December 15, 2023
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "PD-1 Blockade Before AutoSCT in R/R Classic Hodgkin Lymphoma"
FEATURING
Sanjal Desai
- 92 views
- December 29, 2023
- 1
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Harnessing the Immune System in Patients With Lymphoma
FEATURING
Stephen M. Ansell
- 28 views
- November 21, 2023
Insights from 2023 ASH Annual Meeting
Prevalence and Prediction of Ruxolitinib Treatment Emergent Thrombocytopenia in Myelofibrosis
FEATURING
Douglas Tremblay
- 433 views
- December 13, 2023
- 1
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "PROs From BMT CTN 1703 Study in GVHD Prophylaxis - a QoL Evaluation"
FEATURING
Shernan Holtan
- 22 views
- December 22, 2023
Insights from 2023 ASH Annual Meeting
Chronic GVHD: Results from Agave-201 - Axatilimab at 3 Different Doses
FEATURING
Daniel Wolff
- 100 views
- December 29, 2023
Insights from 2023 ASH Annual Meeting
Treatment Strategies for Hematocrit Control in PV
FEATURING
Amy Zhou
- 935 views
- January 8, 2024
- 5
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignancies
FEATURING
Ruemu Birhiray
- 940 views
- April 16, 2024
- 5
Massachusetts General Hospital Cancer Center
Practice-Changing Updates in DLBCL and HL
FEATURING
Julie Erika Haydu
- 313 views
- June 5, 2024
- 3
Total Health
Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL, MM, and CLL
FEATURING
Marcello Maria Rotta
- 257 views
- July 8, 2024
